Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron therapy for pregnancy anaemia
ACTRN12613000853741Phase 4Completed
- Sponsor
- Launceston General Hospital
- Start
- Sep 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in iron deficiency anemia (IDA) comparing Intravenous ferric carboxymaltose, Intravenous iron polymaltose and Standard care oral iron sulfate (3 arms). Primary endpoints: Improvement in haemoglobin and ferritin after treatment, Practical benefits of shorter intravenous iron regimen and 1 more. Started Sep 2013; status: completed.
02
Drugs
ferric carboxymaltoseiron polymaltoseferrous sulfate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ACTRN12613000853741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000853741.